Sign in
Taking people in United StatesPhase 1

Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention

Key facts

Who runs it
Children's Hospital of Philadelphia
Where
Philadelphia, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
15 Apr 2026
Expected to end
31 May 2027
Type of study
Interventional
Treatments tested
  • personalized dosing adjustment of vancomycin
Record updated
18 May 2026

Who can take part

Age
1 month to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age >1 month and <18 years
  • Weight >5kg and <50kg
  • Vancomycin intended duration of therapy ≥48 hours
  • Admitted to intensive care unit with suspected or confirmed sepsis
  • Either sepsis-induced respiratory (invasive mechanical ventilation) or cardiovascular (vasoactive infusion) dysfunction as part of sepsis-associated organ dysfunction (these organ dysfunctions may be improving or resolved at the time of enrollment)

Who cannot take part

  • Extracorporeal support (extracorporeal membrane oxygenation, continuous renal replacement therapy)
  • Patients on chronic dialysis therapy
  • Central nervous system infection
  • Serum creatinine elevated and meets criteria for trough-based dosing by local Clinical Pharmacy
  • Patients with known history of delayed vancomycin clearance based on local pharmacy records
  • Methicillin resistant Staph aureus minimum inhibitory concentration (MIC)>1
  • Pregnancy

This trial is currently available in United States.

  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Alanah McKelveyTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to determine if vancomycin dosing in children with sepsis can be improved by using updated, personalized dosing models that account for new markers of an individual's kidney function. Vancomycin is prescribed based on the known information of how the body breaks this medicine down. Vancomycin may not be effective if blood levels of the medicine are too low. Vancomycin has potential side effects, including the possibility of injury to the kidney. These side effects usually happen when blood levels of vancomycin are too high. There are guidelines for the range of vancomycin blood levels doctors should target to treat an infection and lower the risk of side effects. Children with sepsis may metabolize vancomycin at different rates, faster or slower, than children who do not have sepsis. For these reasons, the current dosing strategy may lead to a higher risk of kidney injury or a risk of not adequately treating an infection in children with sepsis. The investigators' goal is to use new vancomycin dosing equations to improve the ability to select the right dose of vancomycin. The main questions this trial aims to answer are:

Read full original descriptionShow less

1. Is it feasible to use personalized models of vancomycin dosing in children with sepsis? 2. Will personalized models of vancomycin dosing achieve vancomycin blood levels in acceptable ranges?

The group in the trial

  • Personalized vancomycin Pharmacokinetic model for dose adjustmentsTreatment being tested

    Enrolled patients who are prescribed vancomycin by the clinical team will transition to the study-determined empiric vancomycin dosing at the time of enrollment, 12mg/kg/dose administered as an extended intravenous (IV) infusion over 2 hours given every 6 hours. Urinary neutrophil gelatinase-associated lipocalin (NGAL) will be measured as soon as possible after enrollment. Dosage adjustments will be made using the personalized vancomycin pharmacokinetic (PK) model incorporating the NGAL level once resulted. Daily urinary NGAL will be measured while on vancomycin therapy and in the intensive care unit (ICU) to evaluate for ongoing changes in renal function that may necessitate further dosage adjustments using the personalized vancomycin PK model, until clinically stabilized. Patients will undergo vancomycin area under the curve (AUC) monitoring with three timed blood draws for vancomycin concentrations with each vancomycin dosing change with a goal AUC target range of 400-600.

    Treatment: personalized dosing adjustment of vancomycin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Vancomycin and Acute Kidney Injury in Sepsis Treatment - Pharmacologic Modeling Intervention
Record updated
18 May 2026